Compared to conventional treatment alone, Tongxinluo combined with conventional therapy significantly improves total cholesterol, triglycerides, low-density lipoprotein cholesterol, C-reactive protein, interleukin-6, vascular stenosis rate, platelet aggregation rate, and high-density lipoprotein cholesterol in stroke patients, with no noticeable adverse reactions observed during the treatment period. This evidence concerns the gene CRP and stroke disorder.